Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.70 |
| ▸ | FGFR2 | P21802 | 12/20 | 0.70 |
| ▸ | FGFR4 | P22455 | 12/20 | 0.70 |
| ▸ | FGFR3 | P22607 | 12/20 | 0.70 |
| ▸ | KDR | P35968 | 11/20 | 0.70 |
| ▸ | FLT1 | P17948 | 8/20 | 0.68 |
| ▸ | FLT4 | P35916 | 8/20 | 0.68 |
| ▸ | SRC | P12931 | 3/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | CSK | P41240 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | PRKCG | P05129 | 1/20 | 0.45 |
| ▸ | PRKCB | P05771 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | PRKCH | P24723 | 1/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6916832 | 0.82 | FGFR1 (0.63) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL27218125 | 0.82 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL30738031 | 0.82 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL18694599 | 0.82 | FGFR1 (0.68) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL30738006 | 0.81 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL22130753 | 0.81 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL25779717 | 0.81 | FGFR1 (0.73) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL19338047 | 0.80 | FGFR1 (0.82) | FGFR1FGFR2FGFR4FGFR3KDR | |
| Pd-173074 SCHEMBL29828472 | 0.80 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR | |
| Pd-173074 SCHEMBL177946 | 0.80 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037912-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-11-25 | — | — | US | disclosed |
| US-6750241-B2 | Protein kinase inhibitors | THERAVANCE, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020177600-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-11-28 | — | — | US | disclosed |
| US-20020002169-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-01-03 | — | — | US | disclosed |
| WO-2001042243-A2 | PROTEIN KINASE INHIBITORS | ADVANCED MEDICINE, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177600-A1 | Protein kinase inhibitors | MAP3K20, MAP3K9, MAP3K6 | FGFR1 797/4885FGFR2 1381/4885FGFR4 2414/4885 |
| US-20020002169-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | FGFR1 848/4885FGFR2 1173/4885FGFR4 1995/4885 |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | UACA, PRKDC, CDK2 | FGFR1 739/4885FGFR2 1138/4885FGFR4 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.